FRI0503 Can ultrasonographic findings predict response to tumor necrosis factor-a inhibitor treatment in rheumatoid arthritis?
Identifieur interne : 000509 ( Main/Exploration ); précédent : 000508; suivant : 000510FRI0503 Can ultrasonographic findings predict response to tumor necrosis factor-a inhibitor treatment in rheumatoid arthritis?
Auteurs : N. Inanc [Turquie] ; G. Ozen [Turquie] ; H. Direskeneli [Turquie]Source :
- Annals of the Rheumatic Diseases [ 0003-4967 ] ; 2013-06.
Abstract
Background Tumor necrosis factor-α inhibitors (TNFi) are highly effective in patients with rheumatoid arthritis (RA), while not effective in all, with predictors of response being necessary. Although genetic, inflammatory and serologic biomarkers are under major investigation for this purpose, little is known about the predictive value of ultrasonographic parameters in RA. Objectives To investigate the ability of ultrasonographic parameters to predict which patients with RA will benefit from the treatment with TNFi in terms of EULAR response. Methods Biologic naive RA patients starting treatment with TNFi were examined longitudinally by ultrasonography (US) (both Gray-Scale [GS] and Power Doppler [PD]) of 28 joints according to standard scans of EULAR guideline and clinically (tender/swollen joint counts, DAS28 and HAQ scores) at baseline and after 3 months. US examinations were performed by an experienced sonographer (NI) using a MyLab 70 US machine (Esaote, Italy) equipped with 6-18 and 4-13 MHz broad band multi-frequency linear transducer. US synovitis and PD signals were semiquantitatively graded from 0 to 3. Total PD and synovitis scores of all sites are recorded as sum scores of PD and GS, respectively. The clinical response was evaluated according to the EULAR response criteria at 3rd month. Potential ultrasonographic predictors of response were identified using multivariate binary logistic regression models. Results The study cohort consisted of 42 RA patients (F/M=33/9, mean age 49.0±10.7 years) with a mean disease duration of 9.1±7.5 years and mean baseline DAS28 score of 5.5±1.0. Rheumatoid factor (RF) and anti-cyclic citrullinated peptide antibody (CCP) positivity were 76.2% and 64.3%, respectively. Baseline characteristics of TNFi responders (30/42) and non-responders (12/42) are shown in Table 1. Swollen joint count (p= 0.05), sum scores of baseline PD (p= 0.048), GS (p= 0.048) and PD+GS (p= 0.046) differed significantly between responders and non-responders. Baseline PD sum score was the only ultrasonographic parameter in the multivariate analysis predicting which patients achieve good/moderate EULAR response with TNFi at 3rd month (p= 0.004). Conclusions Our data underline that baseline PD scores, despite similar clinical features, can predict which patients will respond to TNFi therapy. Disclosure of Interest None Declared
Url:
DOI: 10.1136/annrheumdis-2013-eular.1630
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: 000A20
- to stream Istex, to step Curation: 000A20
- to stream Istex, to step Checkpoint: 000027
- to stream Main, to step Merge: 000508
- to stream Main, to step Curation: 000509
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">FRI0503 Can ultrasonographic findings predict response to tumor necrosis factor-a inhibitor treatment in rheumatoid arthritis?</title>
<author><name sortKey="Inanc, N" sort="Inanc, N" uniqKey="Inanc N" first="N." last="Inanc">N. Inanc</name>
</author>
<author><name sortKey="Ozen, G" sort="Ozen, G" uniqKey="Ozen G" first="G." last="Ozen">G. Ozen</name>
</author>
<author><name sortKey="Direskeneli, H" sort="Direskeneli, H" uniqKey="Direskeneli H" first="H." last="Direskeneli">H. Direskeneli</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">ISTEX</idno>
<idno type="RBID">ISTEX:606CF2E64819A0871E0B86A6D075B947DC1CEC8A</idno>
<date when="2013" year="2013">2013</date>
<idno type="doi">10.1136/annrheumdis-2013-eular.1630</idno>
<idno type="url">https://api.istex.fr/document/606CF2E64819A0871E0B86A6D075B947DC1CEC8A/fulltext/pdf</idno>
<idno type="wicri:Area/Istex/Corpus">000A20</idno>
<idno type="wicri:Area/Istex/Curation">000A20</idno>
<idno type="wicri:Area/Istex/Checkpoint">000027</idno>
<idno type="wicri:doubleKey">0003-4967:2013:Inanc N:fri:can:ultrasonographic</idno>
<idno type="wicri:Area/Main/Merge">000508</idno>
<idno type="wicri:Area/Main/Curation">000509</idno>
<idno type="wicri:Area/Main/Exploration">000509</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">FRI0503 Can ultrasonographic findings predict response to tumor necrosis factor-a inhibitor treatment in rheumatoid arthritis?</title>
<author><name sortKey="Inanc, N" sort="Inanc, N" uniqKey="Inanc N" first="N." last="Inanc">N. Inanc</name>
<affiliation wicri:level="1"><country xml:lang="fr">Turquie</country>
<wicri:regionArea>Rheumatology, Marmara University School of Medicine, Istanbul</wicri:regionArea>
<wicri:noRegion>Istanbul</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Ozen, G" sort="Ozen, G" uniqKey="Ozen G" first="G." last="Ozen">G. Ozen</name>
<affiliation wicri:level="1"><country xml:lang="fr">Turquie</country>
<wicri:regionArea>Rheumatology, Marmara University School of Medicine, Istanbul</wicri:regionArea>
<wicri:noRegion>Istanbul</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Direskeneli, H" sort="Direskeneli, H" uniqKey="Direskeneli H" first="H." last="Direskeneli">H. Direskeneli</name>
<affiliation wicri:level="1"><country xml:lang="fr">Turquie</country>
<wicri:regionArea>Rheumatology, Marmara University School of Medicine, Istanbul</wicri:regionArea>
<wicri:noRegion>Istanbul</wicri:noRegion>
</affiliation>
</author>
</analytic>
<monogr></monogr>
<series><title level="j">Annals of the Rheumatic Diseases</title>
<title level="j" type="abbrev">Ann Rheum Dis</title>
<idno type="ISSN">0003-4967</idno>
<idno type="eISSN">1468-2060</idno>
<imprint><publisher>BMJ Publishing Group Ltd and European League Against Rheumatism</publisher>
<date type="published" when="2013-06">2013-06</date>
<biblScope unit="volume">72</biblScope>
<biblScope unit="issue">Suppl 3</biblScope>
<biblScope unit="page" from="A544">A544</biblScope>
</imprint>
<idno type="ISSN">0003-4967</idno>
</series>
<idno type="istex">606CF2E64819A0871E0B86A6D075B947DC1CEC8A</idno>
<idno type="DOI">10.1136/annrheumdis-2013-eular.1630</idno>
<idno type="href">annrheumdis-72-A544-3.pdf</idno>
<idno type="ArticleID">annrheumdis-2013-eular.1630</idno>
<idno type="local">annrheumdis;72/Suppl_3/A544-c</idno>
</biblStruct>
</sourceDesc>
<seriesStmt><idno type="ISSN">0003-4967</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass></textClass>
<langUsage><language ident="en">en</language>
</langUsage>
</profileDesc>
</teiHeader>
<front><div type="abstract">Background Tumor necrosis factor-α inhibitors (TNFi) are highly effective in patients with rheumatoid arthritis (RA), while not effective in all, with predictors of response being necessary. Although genetic, inflammatory and serologic biomarkers are under major investigation for this purpose, little is known about the predictive value of ultrasonographic parameters in RA. Objectives To investigate the ability of ultrasonographic parameters to predict which patients with RA will benefit from the treatment with TNFi in terms of EULAR response. Methods Biologic naive RA patients starting treatment with TNFi were examined longitudinally by ultrasonography (US) (both Gray-Scale [GS] and Power Doppler [PD]) of 28 joints according to standard scans of EULAR guideline and clinically (tender/swollen joint counts, DAS28 and HAQ scores) at baseline and after 3 months. US examinations were performed by an experienced sonographer (NI) using a MyLab 70 US machine (Esaote, Italy) equipped with 6-18 and 4-13 MHz broad band multi-frequency linear transducer. US synovitis and PD signals were semiquantitatively graded from 0 to 3. Total PD and synovitis scores of all sites are recorded as sum scores of PD and GS, respectively. The clinical response was evaluated according to the EULAR response criteria at 3rd month. Potential ultrasonographic predictors of response were identified using multivariate binary logistic regression models. Results The study cohort consisted of 42 RA patients (F/M=33/9, mean age 49.0±10.7 years) with a mean disease duration of 9.1±7.5 years and mean baseline DAS28 score of 5.5±1.0. Rheumatoid factor (RF) and anti-cyclic citrullinated peptide antibody (CCP) positivity were 76.2% and 64.3%, respectively. Baseline characteristics of TNFi responders (30/42) and non-responders (12/42) are shown in Table 1. Swollen joint count (p= 0.05), sum scores of baseline PD (p= 0.048), GS (p= 0.048) and PD+GS (p= 0.046) differed significantly between responders and non-responders. Baseline PD sum score was the only ultrasonographic parameter in the multivariate analysis predicting which patients achieve good/moderate EULAR response with TNFi at 3rd month (p= 0.004). Conclusions Our data underline that baseline PD scores, despite similar clinical features, can predict which patients will respond to TNFi therapy. Disclosure of Interest None Declared</div>
</front>
</TEI>
<affiliations><list><country><li>Turquie</li>
</country>
</list>
<tree><country name="Turquie"><noRegion><name sortKey="Inanc, N" sort="Inanc, N" uniqKey="Inanc N" first="N." last="Inanc">N. Inanc</name>
</noRegion>
<name sortKey="Direskeneli, H" sort="Direskeneli, H" uniqKey="Direskeneli H" first="H." last="Direskeneli">H. Direskeneli</name>
<name sortKey="Ozen, G" sort="Ozen, G" uniqKey="Ozen G" first="G." last="Ozen">G. Ozen</name>
</country>
</tree>
</affiliations>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/France/explor/LeHavreV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000509 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000509 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Wicri/France |area= LeHavreV1 |flux= Main |étape= Exploration |type= RBID |clé= ISTEX:606CF2E64819A0871E0B86A6D075B947DC1CEC8A |texte= FRI0503 Can ultrasonographic findings predict response to tumor necrosis factor-a inhibitor treatment in rheumatoid arthritis? }}
This area was generated with Dilib version V0.6.25. |